Prevention of restenosis after percutaneous transluminal coronary angioplasty: the search for a "magic bullet" [PDF]
, 1991 -
Hermans, W.R.M. (Walter) +3 more
core
Clopidogrel-Induced Neutropenia after Coronary Stenting: Is Cilostazol a Good Alternative?
International Journal of Vascular Medicine, 2011 Dual antiplatelet therapy with aspirin plus thienopyridines has become the standard treatment of patients undergoing coronary stenting. Clopidogrel has mostly replaced the use of ticlopidine due to its more favourable adverse event profile. However, also
Massimo Montalto +7 more
doaj +1 more source
Selection of medication in hospitalised elderly patients with Angina Pectoris [PDF]
, 2004 Objective: To evaluate medication changes in hospitalised elderly patients diagnosed with angina pectoris and to compare the selection of medication with evidence-based treatment guidelines. Design: Review of medical notes and patient interview. Setting:
Cacciottolo, Joseph M. +2 more
core
An investigation of the antiplatelet effects of succinobucol (AGI-1067) [PDF]
, 2016 Succinobucol is a phenolic antioxidant with anti-inflammatory and antiplatelet effects. Given the importance of oxidant stress in modulating platelet–platelet and platelet–vessel wall interactions, the aim of this study was to establish if antioxidant ...
Gnanadesika, Sukanya +3 more
core +1 more source
Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Sweden. [PDF]
, 2015 BACKGROUND: Worldwide, coronary heart disease accounts for 7 million deaths each year. In Sweden, acute coronary syndrome (ACS) is a leading cause of hospitalization and is responsible for 1 in 4 deaths.
A Kumar +19 more
core +3 more sources
Качественная клиническая практика, 2018 This article analyzes the volume of the Russian pharmaceutical market of antiplatelet drugs in the period 2014-2016. 80% of patients take clopidogrel generics, giving preference to Zilt®.
S. K. Zyryanov, E. V. Dumchenko
doaj
Acute coronary disease Athero-Inflammation: Therapeutic approach [PDF]
, 2003 Antithrombotic therapy is the cornerstone of the treatment of acute coronary syndromes, but there is now evidence which indicates that by blocking inflammation, thrombosis and thus, acute coronary events, could be lowered.
Altman Raul
core +1 more source
Blood rheology, cardiovascular risk factors, and cardiovascular disease: The West of Scotland Coronary Prevention Study [PDF]
, 2000 The West of Scotland Coronary Prevention Study (WOSCOPS) showed that pravastatin reduced the risk of coronary heart disease (CHD) events in 6,595 middle-aged hypercholesterolaemic men aged 45-64 years without prior myocardial infarction followed for an ...
Ann Rumley +8 more
core +1 more source
Prophylaxis of Experimental Endocarditis With Antiplatelet and Antithrombin Agents: A Role for Long-term Prevention of Infective Endocarditis in Humans? [PDF]
, 2017 Background. Infective endocarditis (IE) mostly occurs after spontaneous low-grade bacteremia. Thus, IE cannot be prevented by circumstantial antibiotic prophylaxis.
Chaouch, Aziz +7 more
core
Advances in Hematology, 2010 Thienopyridines are a class of drug targeting the platelet adenosine diphosphate (ADP) 2 receptor. They significantly reduce platelet activity and are therefore clinically beneficial in settings where platelet activation is a key pathophysiological ...
L. Testa +11 more
doaj +1 more source